Pfizer's (PFE) Prevanar 13 vaccine helped cause a 46% drop in incidents of vaccine-type community-acquired pneumonia (CAPP) in a massive trial of 85,000 patients aged 65 and older when compared with a placebo.
The "trial is the first in adults to clearly demonstrate a significant reduction in vaccine-type pneumococcal CAP," Pfizer said.
The company disclosed the figure when providing details of the study. The firm already said last month that Prevanar 13 met its primary and secondary goals. (PR)